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Response to “Heparin/PF4 antibodies formation
after heparin treatment: Temporal aspects and
long-term follow-up”
We wish to thank Dr Selleng and coauthors for the
interest in our work. They have raised some interesting
issues that we comment on, point-by-point, as follows:
Dr Selleng and coauthors are correct: the 4T score we
present was calculated from the data at day 30 after
surgery (time 2), and therefore, it included all new
thrombotic events that occurred within that period. We
concur with Dr Selleng that this may have contributed to
4T score being rather high in our study. We wish to point
out that this was not part of the initial evaluation of
patients, but it was done retrospectively, in response to a
specific request by one of the reviewers.
We appreciate that statistical methodology can make a
difference. In this respect, we wish to reassure Dr Selleng
and all readers of the Journal that data in Table 2 were not
subjected to Fisher test, but they were actually compared
by using the McNemar χ2 test, which yielded significant
differences. This was specified in the Methods section of
our article (page 590, lines 7-8 of the “Statistical Analysis”
section).1 As for the choice of McNemar χ2 test for
comparing proportions, this approach has been used in
other similar cases.2
Finally, we wish to discuss the implications of our
study, in light of the comments raised by Selleng et al.
However, we first wish to point out that in their letter,
Selleng et al, summarize into one sentence what is actually
the result of a rather articulate series of statements we
made, and therefore the “take home” message may sound
different from what we actually meant. Specifically, we
concluded that:
“Persistence of heparin-induced antibodies in a sub-
stantial number of patients after an initial exposure to UFH
suggests that it would be prudent to limit or avoid the use
of heparin in patients with known history of HIT.” (page
594, lines 27-30). We are confident that there should be no
question that in patients with known history of HIT,
rechallenge with UFH ought to be done with utmost
circumspection, or not at all.
The statement “Recommendations for potential alter-
native anticoagulant therapies among cardiac surgery
patients are based on direct thrombin inhibitors”(page 594, lines 31-33) should then be taken as a logical
consequence of what said above; that is, if UFH cannot be
administered, one should consider alternate thrombin
inhibitors. We believe this concept is also widely
recognized and apologize if it somehow went distorted.
Finally, we wrote “Moreover, the high prevalence of
seropositivity before CABG observed in this study suggests
that it might be advisable to prospectively screen for
positivity all patients scheduled for elective cardiac
surgery, and be on the lookout for possible HIT related
events in this population” (page 594, lines 33-38). We
honestly think that, given the high incidence of antibody
formation, and its potentially relevant clinical conse-
quences, being “on the look out” in CABG patients can be
of benefit in the management of these patients.
As for the idea to screen patients scheduled for CABG,
we feel that as phrased in the sentence above, this is just
as a rather loose suggestion for possible management;
indeed, we entirely concur with Dr Selleng's call for
prospective randomized trials to specifically address this
issue.
We hope that, as an effect of these further clarifica-
tions, our findings may be clearer to the readers of the
Journal. We wish to thank Selleng et al, and the editors, for
the opportunity to provide this further contribution to an
important clinical issue.
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